These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38053931)

  • 1. Nutritional status of adults with phenylketonuria on pegvaliase: A 15-month prospective study.
    Viau K; Martell L; Wessel A; Rohr F; Hollander S; Putman MS; Sacharow S
    Mol Genet Metab Rep; 2023 Dec; 37():101015. PubMed ID: 38053931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutrition status of adults with phenylketonuria treated with pegvaliase.
    Viau K; Wessel A; Martell L; Sacharow S; Rohr F
    Mol Genet Metab; 2021 Aug; 133(4):345-351. PubMed ID: 34116943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Analysis of phase 3 clinical trial data.
    Rohr F; Burton B; Dee A; Harding CO; Lilienstein J; Lindstrom K; MacLeod E; Rose S; Singh R; van Calcar S; Whitehall K
    Mol Genet Metab; 2024 Mar; 141(3):108122. PubMed ID: 38184920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
    Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
    Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
    Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
    Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
    Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J;
    Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria.
    Ishige M; Ito T; Hamazaki T; Kuwahara M; Lee L; Shintaku H
    Mol Genet Metab; 2023 Nov; 140(3):107697. PubMed ID: 37717412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
    Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
    Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nutritional Counseling Promotes Adherence to the Mediterranean Diet and Healthy Eating in Italian Patients Affected by Phenylketonuria and Treated with Pegvaliase.
    Stecchi M; Rossi A; Santoni M; Bandini F; Brodosi L
    Nutrients; 2024 Oct; 16(19):. PubMed ID: 39408315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a practical dietitian road map for the nutritional management of phenylketonuria (PKU) patients on pegvaliase.
    Rocha JC; Bausell H; Bélanger-Quintana A; Bernstein L; Gökmen-Özel H; Jung A; MacDonald A; Rohr F; van Dam E; Heddrich-Ellerbrok M
    Mol Genet Metab Rep; 2021 Sep; 28():100771. PubMed ID: 34094869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.
    Harding CO; Amato RS; Stuy M; Longo N; Burton BK; Posner J; Weng HH; Merilainen M; Gu Z; Jiang J; Vockley J;
    Mol Genet Metab; 2018 May; 124(1):20-26. PubMed ID: 29628378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program.
    Harding CO; Longo N; Northrup H; Sacharow S; Singh R; Thomas JA; Vockley J; Zori RT; Bulloch Whitehall K; Lilienstein J; Lindstrom K; Levy DG; Jones S; Burton BK
    Mol Genet Metab Rep; 2024 Jun; 39():101084. PubMed ID: 38694233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year follow-up of B vitamin and Iron status in patients with phenylketonuria provided tetrahydrobiopterin (BH4).
    Brantley KD; Douglas TD; Singh RH
    Orphanet J Rare Dis; 2018 Oct; 13(1):192. PubMed ID: 30373601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
    Longo N; Zori R; Wasserstein MP; Vockley J; Burton BK; Decker C; Li M; Lau K; Jiang J; Larimore K; Thomas JA
    Orphanet J Rare Dis; 2018 Jul; 13(1):108. PubMed ID: 29973227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary Investigation of Microbiome and Dietary Differences in Patients with Phenylketonuria on Enzyme Substitution Therapy Compared to Traditional Therapies.
    McWhorter N; Dhillon J; Hoffman J
    J Acad Nutr Diet; 2022 Jul; 122(7):1283-1295.e3. PubMed ID: 34968752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuria.
    Burton BK; Clague GE; Harding CO; Kucuksayrac E; Levy DG; Lindstrom K; Longo N; Maillot F; Muntau AC; Rutsch F; Zori RT
    Mol Genet Metab; 2024 Jan; 141(1):108114. PubMed ID: 38142628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences.
    SriBhashyam S; Marsh K; Quartel A; Weng HH; Gershman A; Longo N; Thomas J; Zori R
    Mol Genet Metab Rep; 2019 Dec; 21():100507. PubMed ID: 31497506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutrient intake, body composition, and blood phenylalanine control in children with phenylketonuria compared to healthy controls.
    Sailer M; Elizondo G; Martin J; Harding CO; Gillingham MB
    Mol Genet Metab Rep; 2020 Jun; 23():100599. PubMed ID: 32420034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in body composition and bone mineral density in phenylketonuria: A cross-sectional study.
    Stroup BM; Hansen KE; Krueger D; Binkley N; Ney DM
    Mol Genet Metab Rep; 2018 Jun; 15():30-35. PubMed ID: 30023287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegvaliase treatment normalizes blood neurotransmitter metabolites in adults with phenylketonuria.
    Sigg MA; Wilson C; Clague GE; Zhou H; Su C; Berguig GY
    Mol Genet Metab; 2024 Nov; 143(3):108580. PubMed ID: 39388898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.